Coherus BioSciences (NASDAQ:CHRS) and Forma Therapeutics (NASDAQ:FMTX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk and profitability.
This is a summary of recent recommendations and price targets for Coherus BioSciences and Forma Therapeutics, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Institutional and Insider Ownership
67.3% of Forma Therapeutics shares are held by institutional investors. 15.9% of Coherus BioSciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
This table compares Coherus BioSciences and Forma Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings & Valuation
This table compares Coherus BioSciences and Forma Therapeutics’ top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Coherus BioSciences||$356.07 million||2.90||$89.83 million||$1.23||11.54|
|Forma Therapeutics||$100.56 million||11.45||-$34.79 million||N/A||N/A|
Coherus BioSciences has higher revenue and earnings than Forma Therapeutics.
Coherus BioSciences beats Forma Therapeutics on 6 of the 11 factors compared between the two stocks.
About Coherus BioSciences
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its product candidate pipeline includes biosimilars of Humira, Avastin, and Lucentis. The company also develops Toripalimab, a novel anti-PD-1 antibody for second-line treatment of melanoma in China; Bevacizumab biosimilar; CHS-1420, an anti-TNF product candidate, as an adalimumab biosimilar; Ranibizumab biosimilar; and CHS-131, a once-daily oral drug candidate for non-alcoholic steatohepatitis and other metabolic conditions. Coherus BioSciences, Inc. has license agreements with Selexis SA; AbbVie, Inc.; Pfizer, Inc.; Bioeq AG; Innovent Biologics (Suzhou) Co., Ltd.; and Junshi Biosciences. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was founded in 2010 and is headquartered in Redwood City, California.
About Forma Therapeutics
Forma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers. Its core product candidates for development include FT-4202, which is Phase 1 trial for the treatment of sickle cell disease and other hemoglobinopathies; and FT-7051 for the treatment of metastatic castration-resistant prostate cancer. The company is also developing FT-2102, an oral selective small molecule investigational agent that is designed to bind to and inhibit mutated IDH1 enzymes, which is being evaluated in a Phase 2 trial for relapsed/refractory AML, as well as an exploratory Phase 1 trial for glioma; and FT-4101 and FT-8225, which are selective fatty acid synthase inhibitors. The company was founded in 2007 and is headquartered in Watertown, Massachusetts.
Receive News & Ratings for Coherus BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.